Patent US4375464A successfully refreshed from Google Patents.
US4375464A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Antibiotic AY24,668 and process of preparation
Assignee: Wyeth Canada Inc
•
Filing: 1981-11-19
•
Granted: 1983-03-01
•
Expires: 2001-11-19
Abstract
Abstract Antibiotic AY24,668 is producible by culturing Streptomyces hygroscopicus NRRL 5491 in an aqueous nutrient medium. AY24,668 has antifungal properties. Methods for its preparation and use are disclosed.
Inventors
- 👤 Surendra N. Sehgal
- 👤 Claude Vezina
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-07 17:49
CPC Classifications
C; C12; C12P; C12P1/00; C12P1/06; C12N; C12N1/00; C12N1/20; C12N1/205; A; A61; A61P; A61P31/00; A61P31/04; A61P31/10; C12R; C12R2001/00; C12R2001/01; C12R2001/465; C12R2001/55
Claims Analysis
Total Claims: 6
Claim 1
Independent Claim
159 words
Solid AY24,668, an antibiotic which a. gives a colorless, crystalline compound with a melting point of 122° to 124° C., after recrystallization from diethyl ether; b. is soluble in diethyl ether, chloroform, acetone, methanol and dimethylformamide, very sparingly soluble in hexane and petroleum ether and substantially insoluble in water; c. shows a uniform spot on thin layer plates of silica gel; d. has a characteristic elemental analysis of about C, 67.75%, H, 8.93% N, 1.72%; e. exhibits the following characteristic absorption maxima in its ultraviolet absorption spectrum (95% ethanol): 267 nm (E 1cm 1% 421), 277 nm (E 1cm 1% 549) and 288 nm (E 1cm 1% 423); f. has a characteristic infrared absorption spectrum shown in accompanying FIG. 1; g. has a characteristic nuclear magnetic resonance spectrum as shown in accompanying FIG. 2; h. has a minimum inhibitory concentration of 0.36 to 10.0 μg/ml against Candida albicans; and i. exhibits a LD 50 (i.p., mice) of >900 mg/kg.
Claim 2
Dependent Claim
159 words
Solid AY24,668, an antibiotic which a. gives a colorless, crystalline compound with a melting point of 122° to 124° C., after recrystallization from diethyl ether; b. is soluble in diethyl ether, chloroform, acetone, methanol and dimethylformamide, very sparingly soluble in hexane and petroleum ether and substantially insoluble in water; c. shows a uniform spot on thin layer plates of silica gel; d. has a characteristic elemental analysis of about C, 67.75%, H, 8.93% N, 1.72%; e. exhibits the following characteristic absorption maxima in its ultraviolet absorption spectrum (95% ethanol): 267 nm (E 1cm 1% 421), 277 nm (E 1cm 1% 549) and 288 nm (E 1cm 1% 423); f. has a characteristic infrared absorption spectrum shown in accompanying FIG. 1; g. has a characteristic nuclear magnetic resonance spectrum as shown in accompanying FIG. 2; h. has a minimum inhibitory concentration of 0.36 to 10.0 μg/ml against Candida albicans; and i. exhibits a LD 50 (i.p., mice) of >900 mg/kg.
Claim 3
Dependent Claim
176 words
A pharmaceutical composition which comprises a pharmaceutically acceptable carrier and an antifungal effective amount of the antibiotic AY24,668 which a. is a solid giving a colorless, crystalline compound with a melting point of 122° to 124° C., after recrystallization from diethyl ether; b. is soluble in diethyl ether, chloroform, acetone, methanol and dimethylformamide, very sparingly soluble in hexane and petroleum ether and substantially insoluble in water; c. shows a uniform spot on thin layer plates of silica gel; d. has a characteristic elemental analysis of about C, 67.75%, H, 8.93% N, 1.72%; e. exhibits the following characteristic absorption maxima in its ultraviolet absorption spectrum (95% ethanol): 267 nm (E 1cm 1% 421), 277 nm (E 1cm 1% 549) and 288 nm (E 1cm 1% 423); f. has a characteristic infrared absorption spectrum shown in accompanying FIG. 1; g. has a characteristic nuclear magnetic resonance spectrum as shown in accompanying FIG. 2; h. has a minimum inhibitory concentration of 0.36 to 10.0 μg/ml against Candida albicans; and i. exhibits a LD 50 (i.p., mice) of >900 mg/kg.
Claim 4
Dependent Claim
176 words
A pharmaceutical composition which comprises a pharmaceutically acceptable carrier and an antifungal effective amount of the antibiotic AY24,668 which a. is a solid giving a colorless, crystalline compound with a melting point of 122° to 124° C., after recrystallization from diethyl ether; b. is soluble in diethyl ether, chloroform, acetone, methanol and dimethylformamide, very sparingly soluble in hexane and petroleum ether and substantially insoluble in water; c. shows a uniform spot on thin layer plates of silica gel; d. has a characteristic elemental analysis of about C, 67.75%, H, 8.93% N, 1.72%; e. exhibits the following characteristic absorption maxima in its ultraviolet absorption spectrum (95% ethanol): 267 nm (E 1cm 1% 421), 277 nm (E 1cm 1% 549) and 288 nm (E 1cm 1% 423); f. has a characteristic infrared absorption spectrum shown in accompanying FIG. 1; g. has a characteristic nuclear magnetic resonance spectrum as shown in accompanying FIG. 2; h. has a minimum inhibitory concentration of 0.36 to 10.0 μg/ml against Candida albicans; and i. exhibits a LD 50 (i.p., mice) of >900 mg/kg.
Claim 5
Independent Claim
184 words
A method of inhibiting the growth of pathogenic fungi in a mammal which comprises administering to the mammal an antifungally effective amount of the antibiotic AY24,668 which a. is a solid giving a colorless, crystalline compound with a melting point of 122° to 124° C., after recrystallization from diethyl ether; b. is soluble in diethyl ether, chloroform, acetone, methanol and dimethylformamide, very sparingly soluble in hexane and petroleum ether and substantially insoluble in water; c. shows a uniform spot on thin layer plates of silica gel; d. has a characteristic elemental analysis of about C, 67.75%, H, 8.93% N, 1.72%; e. exhibits the following characteristic absorption maxima in its ultraviolet absorption spectrum (95% ethanol): 267 nm (E 1cm 1% 421), 277 nm (E 1cm 1% 549) and 288 nm (E 1cm 1% 423); f. has a characteristic infrared absorption spectrum shown in accompanying FIG. 1; g. has a characteristic nuclear magnetic resonance spectrum as shown in accompanying FIG. 2; h. has a minimum inhibitory concentration of 0.36 to 10.0 μg/ml against Candida albicans; and i. exhibits a LD 50 (i.p., mice) of >900 mg/kg.
Claim 6
Independent Claim
184 words
A method of inhibiting the growth of pathogenic fungi in a mammal which comprises administering to the mammal an antifungally effective amount of the antibiotic AY24,668 which a. is a solid giving a colorless, crystalline compound with a melting point of 122° to 124° C., after recrystallization from diethyl ether; b. is soluble in diethyl ether, chloroform, acetone, methanol and dimethylformamide, very sparingly soluble in hexane and petroleum ether and substantially insoluble in water; c. shows a uniform spot on thin layer plates of silica gel; d. has a characteristic elemental analysis of about C, 67.75%, H, 8.93% N, 1.72%; e. exhibits the following characteristic absorption maxima in its ultraviolet absorption spectrum (95% ethanol): 267 nm (E 1cm 1% 421), 277 nm (E 1cm 1% 549) and 288 nm (E 1cm 1% 423); f. has a characteristic infrared absorption spectrum shown in accompanying FIG. 1; g. has a characteristic nuclear magnetic resonance spectrum as shown in accompanying FIG. 2; h. has a minimum inhibitory concentration of 0.36 to 10.0 μg/ml against Candida albicans; and i. exhibits a LD 50 (i.p., mice) of >900 mg/kg.
References Cited (Backward Citations)
US3929992A
Cited
US3993749A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1986-02-28 | 1986-08-30 | 1987-03-01 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1990-02-28 | 1990-08-30 | 1991-03-01 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1994-02-28 | 1994-08-30 | 1995-03-01 | $7700.00 | Window Closed / Lapsed |